Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Inhibrx Biosciences, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +14 vs. Q3 2022
- Shares held
- 36.0M
- +7.43M (+26.0%) vs. Q3 2022
- Total value
- $886.0M
- +$373.8M (+73.0%) vs. Q3 2022
- New holders
- 24
- 50 more added
- Sold out
- 10
- 31 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 478,302 | $11.8M | 1.69% | +114,400+31.4% | Added |
| Geode Capital Management, LLC | 575,697 | $14.2M | 0.00% | +78,890+15.9% | Added |
| Millennium Management LLC | 697,836 | $17.2M | 0.02% | +201,410+40.6% | Added |
| Point72 Asset Management, L.P. | 752,500 | $18.5M | 0.07% | +295,400+64.6% | Added |
| Wellington Management Group LLP | 900,982 | $22.2M | 0.00% | −111,758−11.0% | Reduced |
| Loomis Sayles & Co L P | 1,000,806 | $24.7M | 0.05% | −23,938−2.3% | Reduced |
| Sofinnova Investments, Inc. | 1,110,183 | $27.4M | 1.66% | +660,006+146.6% | Added |
| ArrowMark Colorado Holdings LLC | 1,139,337 | $28.1M | 0.34% | −199,690−14.9% | Reduced |
| MPM Oncology Impact Management LP | 1,286,435 | $31.7M | 8.22% | +6,440+0.5% | Added |
| FMR LLC | 1,690,635 | $41.7M | 0.00% | −68,820−3.9% | Reduced |
| Vanguard Group Inc | 1,760,373 | $43.4M | 0.00% | +292,455+19.9% | Added |
| BlackRock Inc. | 2,416,188 | $59.5M | 0.00% | +225,670+10.3% | Added |
| State Street Corp | 2,506,988 | $61.8M | 0.00% | +466,934+22.9% | Added |
| Perceptive Advisors LLC | 3,313,783 | $81.7M | 2.35% | +425,923+14.7% | Added |
| Ra Capital Management, L.P. | 3,853,867 | $95.0M | 1.93% | +3,853,867 | New |
| Viking Global Investors LPSuperinvestorViking Global Investors | 6,639,199 | $163.6M | 0.82% | +1,333,333+25.1% | Added |
| Opaleye Management Inc. | 0 | $0 | 0.00% | −292,700−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −103,097−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −71,297−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −49,318−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −20,358−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −16,912−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −13,301−100.0% | Sold out |
| Lido Advisors, LLC | 0 | $0 | 0.00% | −11,549−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −6,260−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −123−100.0% | Sold out |